WallStreetZenWallStreetZen

NASDAQ: ALLR
Allarity Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALLR

Based on 1 analyst offering 12 month price targets for Allarity Therapeutics Inc

Min Forecast
$9.50+685.12%
Avg Forecast
$9.50+685.12%
Max Forecast
$9.50+685.12%

Should I buy or sell ALLR stock?

Based on 1 analyst offering ratings for Allarity Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALLR's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ALLR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ALLR stock forecasts and price targets.

ALLR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-09

1 of 1

Forecast return on equity

Is ALLR forecast to generate an efficient return?

Company
-3,383.8%
Industry
90.09%
Market
344.83%
ALLR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALLR forecast to generate an efficient return on assets?

Company
-1,954.36%
Industry
27.98%
ALLR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALLR earnings per share forecast

What is ALLR's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.99-110.88%
Avg 2 year Forecast
-$25.70-382.77%

ALLR revenue forecast

What is ALLR's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$8.8M

ALLR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALLR$1.14$9.50+733.33%Buy
MTVA$8.17$40.00+389.78%Buy
KAPA$0.88$9.00+922.73%Strong Buy
CVKD$8.53N/AN/A
LSTA$2.08$23.50+1,029.81%Strong Buy
View Top Biotech Stocks

Allarity Therapeutics Stock Forecast FAQ

Is Allarity Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ALLR) stock is to Buy ALLR stock.

Out of 1 analyst, 0 (0%) are recommending ALLR as a Strong Buy, 1 (100%) are recommending ALLR as a Buy, 0 (0%) are recommending ALLR as a Hold, 0 (0%) are recommending ALLR as a Sell, and 0 (0%) are recommending ALLR as a Strong Sell.

If you're new to stock investing, here's how to buy Allarity Therapeutics stock.

What is ALLR's earnings growth forecast for 2026-2027?

(NASDAQ: ALLR) Allarity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 209.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,149.06%.

Allarity Therapeutics's earnings in 2026 is -$15,311,000.On average, 3 Wall Street analysts forecast ALLR's earnings for 2026 to be -$15,644,280, with the lowest ALLR earnings forecast at -$15,030,779, and the highest ALLR earnings forecast at -$16,104,406.

In 2027, ALLR is forecast to generate -$406,428,718 in earnings, with the lowest earnings forecast at -$390,490,337 and the highest earnings forecast at -$418,382,504.

What is ALLR's revenue growth forecast for 2026-2027?

(NASDAQ: ALLR) Allarity Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11,497.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,476.92%.

Allarity Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ALLR's revenue for 2026 to be $0, with the lowest ALLR revenue forecast at $0, and the highest ALLR revenue forecast at $0.

In 2027, ALLR is forecast to generate $138,480,498 in revenue, with the lowest revenue forecast at $133,041,209 and the highest revenue forecast at $142,544,152.

What is ALLR's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: ALLR) forecast ROA is -1,954.36%, which is lower than the forecast US Biotechnology industry average of 28.13%.

What is ALLR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ALLR price target, the average ALLR price target is $9.50, with the highest ALLR stock price forecast at $9.50 and the lowest ALLR stock price forecast at $9.50.

The Wall Street analyst predicted that Allarity Therapeutics's share price could reach $9.50 by Dec 9, 2026. The average Allarity Therapeutics stock price prediction forecasts a potential upside of 733.33% from the current ALLR share price of $1.14.

What is ALLR's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ALLR) Allarity Therapeutics's current Earnings Per Share (EPS) is $9.09. On average, analysts forecast that ALLR's EPS will be -$0.99 for 2026, with the lowest EPS forecast at -$0.95, and the highest EPS forecast at -$1.02. In 2027, ALLR's EPS is forecast to hit -$25.70 (min: -$24.70, max: -$26.46).

What is ALLR's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: ALLR) forecast ROE is -3,383.8%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.